Three-phase treatment offers patients with HSV infections an alternative to perpetual antiviral management ROATAN, BAY ...
The new oral therapy demonstrates superior lesion healing for complex patients who have few current treatment options.
A phase 3 trial finds pritelivir significantly improves cure rates for immunocompromised individuals with refractory HSV infections.
- Treatment with EBT-104 led to complete elimination of viral shedding in 92% eyes of treated rabbits - Excision’s proprietary gene editing technology holds unique, curative potential to address the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results